Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Hepatitis

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Lancet

Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, Tomah S, Gutierrez JA, Urbina S, Suschak JJ, Brown R, Odili O, Yang J, Keeton S, Neff G, Mena E, Roberts MS, Browne SK, Harris MS

doi: 10.1016/S0140-6736(25)02114-2

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Gastritis

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators

doi: 10.1016/S2468-1253(26)00116-0

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Reinisch W, Stepek D, Kempinski R, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Jairath V

doi: 10.1016/S2468-1253(26)00120-2

Gallbladder and Biliary Diseases

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group

doi: 10.1016/S2468-1253(25)00192-X

Hepatology

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial

Hepatology

Dasarathy S, Mitchell EP, Wilson LA, Neuschwander-Tetri BA, Chalasani N, Clark JM, Diehl AM, Hameed B, Loomba R, Yuan L, Kowdley KV, Sanyal AJ, NASH Clinical Research Network

doi: 10.1097/HEP.0000000000001797

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Jairath V, Kierkuś J, Duvall GA, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Reinisch W

doi: 10.1016/S2468-1253(26)00119-6

Further Publications

Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial

BMC Gastroenterol

Ramadan AM, El-Wakeel LM, Adel A, Abdel-Wahab M, Fahmy SF

doi: 10.1186/s12876-026-05157-x

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

Related content

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study